{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:07:57Z","timestamp":1753182477200,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,28]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Progression-free survival in first line is 12 months, overall survival is 23 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034349","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T22:03:25Z","timestamp":1696629805000},"page":"e34349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4283-0554","authenticated-orcid":false,"given":"Liang-Ke","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Lang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Yuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Bo","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"1358","article-title":"Multiple primary malignant tumors. A survey of the literature and a statistical study.","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"R2-20250504","first-page":"384","article-title":"Multiple primary malignancies.","volume":"133","author":"Bisof","year":"2011","journal-title":"Lijec Vjesn"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment.","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","article-title":"Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy.","volume":"24","author":"Li","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review.","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/a-1083-6962","article-title":"Das diffuse maligne peritoneale Mesotheliom (DMPM) \u2013 eine seltene Diagnose.","volume":"58","author":"Habbel","year":"2020","journal-title":"Z Gastroenterol"},{"key":"R9-20250504","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-021-01125-z","article-title":"Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.","volume":"16","author":"Pezzuto","year":"2021","journal-title":"Diagn Pathol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"839","DOI":"10.21873\/anticanres.13183","article-title":"Malignant peritoneal mesothelioma: treatment options and survival.","volume":"39","author":"Salo","year":"2019","journal-title":"Anticancer Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","article-title":"Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.","volume":"34","author":"Chapel","year":"2021","journal-title":"Modern Pathol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e2119934","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma.","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti\u2013PD-L1 antibody avelumab.","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/imt-2019-0131","article-title":"Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer.","volume":"12","author":"Reinhorn","year":"2020","journal-title":"Immunotherapy"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages.","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/modpathol.3800245","article-title":"Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma.","volume":"18","author":"Kimura","year":"2005","journal-title":"Mod Pathol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment.","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:07:11Z","timestamp":1746324431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":19,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034349","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}